[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632891":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":19,"locations":25,"responsibleParty":41,"collaborators":11,"id":43,"slug":11,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":11,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":11,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":11,"overallStatus":61,"whyStopped":11,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"Keymed Biosciences Co.Ltd","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CM512","EXPERIMENTAL",null,[13],"Biological: CM512",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"BIOLOGICAL","Administered subcutaneous injection",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":11,"email":24},"Qian Jia","CONTACT","028-88610620","clinicaltrial@keymedbio.com",[26],{"facility":27,"status":11,"city":28,"state":11,"zip":11,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Beijing Tong-Ren hospital","Beijing","China","CN",{"type":32,"coordinates":33},"Point",[34,35],116.39723,39.9075,{"lat":35,"lon":34},[38],{"name":39,"role":22,"phone":40,"phoneExt":11,"email":24},"Luo Zhang","010-58268486-8009",{"type":42,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100632891",false,"NCT07519577","A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （NEZHA-2）","An Open-Label, Single-Arm, Multicenter, Extension Study to Evaluate the Safety and Efficacy of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis","Inclusion Criteria:\n\n* Participated in the clinical study of CM512 in patients with Chronic Rhinosinusitis with Nasal Polyposis (Study No. of CM512-102101) .\n\nExclusion Criteria:\n\n* Not enough washing out period for previous therapy, e.g., less than 10 weeks or 5 half-lives (whichever is longer) for Interleukin (IL)-4 receptor alpha subunit antagonists, less than 8 weeks or 5 half-lives for biologic therapy\u002Fsystemic immunosuppressant, less than 6 months for sinus surgery (including polypectomy).With malignant or benign tumor of nasal cavity.\n* Administration of a live attenuated vaccine within 30 days prior to baseline or planning to receive one during the study period.","ALL","18 Years","75 Years",{"count":53,"type":54},120,"ESTIMATED","INTERVENTIONAL",[57],"PHASE2","This is an open-label, single-arm, multicenter, extension study to evaluate the safety and efficacy of CM512 in patients With Chronic Rhinosinusitis with Nasal Polyposis",[60],"Chronic Rhinosinusitis With Nasal Polyposis","NOT_YET_RECRUITING","2026-06-26",{"date":64,"type":65},"2026-06-30","ACTUAL",{"date":67,"type":54},"2026-05-31",{"date":69,"type":54},"2028-05-31",{"name":5,"class":6},1]